» Articles » PMID: 32574836

5-Fluorouracil Induced Dysregulation of the Microbiome-gut-brain Axis Manifesting As Depressive Like Behaviors in Rats

Overview
Publisher Elsevier
Date 2020 Jun 24
PMID 32574836
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Disturbances of the gut microbiome have been widely suggested to be associated with 5-fluorouracil (5-Fu) induced digestive pathologies. Furthermore, it has been elucidated that the gut microbiome may play a key role in the pathogenesis of depressive disorders via the microbiota-gut-brain axis. Despite the speculation, there exists no direct evidence proving the causality between disturbances in the gut microbiome induced by 5-Fu and depressive mood dysregulation. Herein, behavioral testing was used to evaluate depressive-like behaviors in 5-Fu treated rats. Subsequently, the gut microbiota and prefrontal cortex (PFC) metabolic were analyzed by 16S rRNA sequencing and H nuclear magnetic resonance (H NMR). To clarify the association between the gut microbiota and their role on depressive-like behaviors caused by 5-Fu, a fecal microbiota transplantation (FMT) experiment was carried out. The results suggested that 5-Fu could significantly alter the diversity and abundance of the gut microbiome, and induce PFC metabolic disorders, as well as depressive behaviors in rats. Transplantation of fecal microbiota from healthy control into 5-Fu treated rats significantly alleviated the PFC metabolic disorder and depressive-like behaviors. In conclusion, this study demonstrated that the gut microbiome was actively involved in the occurrence of 5-Fu induced depressive-like behaviors, and manipulation of specific gut microbiome parameters may serve as a promising novel target for side effects of 5-Fu treatment.

Citing Articles

Lentinan's effect on gut microbiota and inflammatory cytokines in 5-FU-induced mucositis mice.

Zhang X, Wang L, Khan A, Rehman A, Khinsar K, Xin Y AMB Express. 2025; 15(1):11.

PMID: 39843881 PMC: 11754778. DOI: 10.1186/s13568-024-01796-z.


Current trends and hotspots of depressive disorders with colorectal cancer: A bibliometric and visual study.

Yan Z, Liu Y, Xu Q, Yuan Y World J Gastrointest Oncol. 2024; 16(8):3687-3704.

PMID: 39171183 PMC: 11334043. DOI: 10.4251/wjgo.v16.i8.3687.


Current landscape of fecal microbiota transplantation in treating depression.

Zhang Q, Bi Y, Zhang B, Jiang Q, Mou C, Lei L Front Immunol. 2024; 15:1416961.

PMID: 38983862 PMC: 11231080. DOI: 10.3389/fimmu.2024.1416961.


The Gut Microbiota and Major Depressive Disorder: Current Understanding and Novel Therapeutic Strategies.

Bahmani M, Mehrtabar S, Jafarizadeh A, Zoghi S, Sadeghpour Heravi F, Abbasi A Curr Pharm Biotechnol. 2024; 25(16):2089-2107.

PMID: 38288791 DOI: 10.2174/0113892010281892240116081031.


Pharmacomicrobiomics of cell-cycle specific anti-cancer drugs - is it a new perspective for personalized treatment of cancer patients?.

Kazmierczak-Siedlecka K, Bulman N, Ulasinski P, Sobocki B, Polom K, Marano L Gut Microbes. 2023; 15(2):2281017.

PMID: 37985748 PMC: 10730203. DOI: 10.1080/19490976.2023.2281017.